WRAIR scientists and partners developed an mRNA vaccine that protects against malaria in animal models. Malaria remains a large public health and economic burden worldwide as well as a danger to deployed Service Members. This vaccine uses mRNA accompanied by a lipid nanoparticle to prompt cells to code for circumsporozoite protein, which then triggers an immune response against malaria. The vaccine achieved high levels of protection in mice, encouraging further development for the novel platform.
What The Study Did: Researchers reviewed access to COVID-19 vaccination sites in Brooklyn, the most populated borough in New York, to better understand disparities in vaccination.
A faster method for collecting pure malaria parasites from infected mosquitos could accelerate the development of new, more potent malaria vaccines.
Researchers from the Hospital del Mar and Pompeu Fabra University have confirmed that messenger RNA vaccines pre-prepared in syringes for their administration can be transported by road for up to three hours. The researchers have conducted stress tests on syringes pre-prepared for administering the Pfizer BioNTech and Moderna vaccines, and have found that the vector these vaccines use, the messenger RNA, maintains its integrity despite being subjected to movement.
A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open the door to even more effective and powerful vaccines against the coronavirus and its rapidly emerging variants.
Research published in the journal ACS Materials and Interfaces has provided new understanding of how false-negative results in Lateral Flow Tests occur and provides opportunity for simple improvements to be made.
New research published in BMJ Open shows that community pharmacy could play a 'key clinical role' in the future of COVID-19 vaccination programmes, according to a study led by Aston University in Birmingham, UK, in collaboration with UK and international researchers.
What The Study Did:Â This study demonstrated an association between receiving the mRNA-1273 (Moderna) vaccine and a reduction in SARS-CoV-2 infection in health care workers beginning eight days after the first dose.
Evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic was unprecedented in terms of urgency and scope. Responsibility for the safety, integrity and scientific validity of U.S. trials fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board, who in turn report to an oversight group. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.
A review of more than 9,000 US patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from a study conducted by researchers from the University of Missouri School of Medicine and MU Health Care.